1	Full Title: Radiomic Profiling of Chest CT in a Cohort of Sarcoidosis Cases							
2								
3	Authors: Nichole E Carlson, PhD ¹ , William Lippitt, MS, PhD ¹ , Sarah M Ryan, PhD ¹ ,							
4	Margaret Mroz, MS ² , Briana Barkes, MPH ² , Shu-Yi Liao, MD, MPH,ScD ^{2,3,4} , Lisa A							
5	Maier, MD ^{2,3,4*} , Tasha E Fingerlin, PhD ^{1,5*} .							
6								
7	*These authors contributed equally to this work.							
8								
9	Institutions: ¹ Colorado School of Public Health, Department of Biostatistics and							
10	Informatics; ² National Jewish Health, Department of Medicine; ³ University of Colorado,							
11	Department of Medicine; ⁴ Colorado School of Public Health, Department of Environmental							
12	and Occupational Health; ⁵ National Jewish Health, Department of Immunology and							
13	Genomic Medicine;							
14								
15 16 17 18 19 20 21 22 23 24 25 26 27 28	Corresponding Author: Nichole E Carlson, PhD Professor Department of Biostatistics and Informatics University of Colorado-Anschutz Medical Campus 13001 E 17 th PL, MS B-119 Aurora, CO 80045 Tel: 303-724-4354 Fax:303-724-4491 e-mail:nichole.carlson@cuanschutz.edu							
29	Running Head: Radiomic Profiling of Sarcoidosis of the Lung							

30 **Total Word Count:** 3200

31

- 32 **Supplementary Material Statement:** This article has an online supplement, which is
- 33 accessible from this issue's table of contents online.

34

35 Summary of COI:

- 36
- NEC, WLL, MM, TEF, SL, BB, TEF have received grants from the National Institutes of Health (R01 HL114587; R01 HL142049; U01 HL112695; U01 HL112707; U01
- 39 HL112707, U01 HL112694, U01 HL112695, U01 HL112696, U01 HL112702, U01
- 40 HL112708, U01 HL112711, U01 HL112712)
- 41
- 42 WLL is additionally support on National Institutes of Health 5T32HL007085
- 43
- LAM has received grants from the National Institute of Health (R01HL140357,
- 45 R01HL142049, R01 HL114587; U01 HL112695; U01 HL112707; U01 HL112707, U01
- 46 HL112694, U01 HL112695, U01 HL112696, U01 HL112702, U01 HL112708, U01
- 47 HL112711, U01 HL112712, and R01HL136681), Ann Theodore Foundation, the FSR,
- 48 Mallinckrodt Pharmaceuticals, and the University of Cincinnati (Mallinckrodt
- 49 Pharmaceuticals Foundation Grant) and serves on the Scientific Advisory Board for
- 50 FSR, and Boeringer Ingelheim.
- 51

Funding: This work is supported by NIH grants: R01 HL114587; R01 HL142049; U01
HL112695; U01 HL112707; U01 HL112707, U01 HL112694, U01 HL112695, U01
HL112696, U01 HL112702, U01 HL112708, U01 HL112711, U01 HL112712 and
5T32HL007085

- 56
- 57 Acknowledgements and Author contributions: NEC is responsible for all content in
- 58 the manuscript.
- 59
- 60 N.E.C. Substantial contributions to the conception or design of the work, lead
- 61 biostatistical analysis and interpretation of the data and wrote manuscript. W.L.
- 62 developed the filtering method for this analysis, performed the sensitivity and validation
- analyses and edited the manuscript. S.M.R. performed image processing, conducted

64	statistical analysis, prepared figures and table, interpreted the data, and contributed to
65	the manuscript. M.M. coordinated the study, cleaned data, and contributed to the
66	manuscript. B.B. supported data acquisition, data cleaning, project management, and
67	contributed to the manuscript. S.L. contributed to the scientific rationale and
68	interpretation of the data and contributed to the manuscript. L.A.M. Substantial
69	contributions to the conception or design of the work, interpretation of the data and
70	wrote the manuscript. T.E.F. Substantial contributions to the conception or design of the
71	work, interpretation of the data and wrote the manuscript.
72	
73	This work was supported by the National Institutes of Health (R01 HL114587; R01
74	HL142049; U01 HL112695; T32HL007085). Data from the GRADS study was used,
75	which was funded by the NIH grant U01 HL112707 entitled "Sarcoidosis and A1AT
76	Genomics and Informatics Centre", as well as others (U01 HL112707, U01 HL112694,
77	U01 HL112695, U01 HL112696, U01 HL112702, U01 HL112708, U01 HL112711, U01
78	HL112712). The content is solely the responsibility of the authors and does not
79	necessarily represent the official views of the National Heart, Lung, and Blood Institute
80	or the National Institutes of Health.

- 1 Key words: quantitative imaging, texture analysis, pulmonary function, phenotyping,
- 2 patient outcomes
- 3

4 Abbreviations:

- 5 AD Airway and Vascular Distortion
- 6 BMI body mass index
- 7 BVB bronchovascular bundle
- 8 HRCT High resolution chest computed tomography
- 9 CXR chest X-ray
- 10 DLCO diffusing capacity for carbon monoxide
- 11 FEV1 forced expiratory volume in one second
- 12 FEV1/FVC ratio of FEV1 to FVC
- 13 FVC forced vital capacity
- 14 GIC Genetics and Informatics Core
- 15 GLCM Gray level co-occurrence matrix
- 16 GRADS Genomic Research in Alpha-1 Anti-trypsin Deficiency and Sarcoidosis
- 17 IRB institutional review board
- 18 LN lymphadenopathy
- 19 PA parenchymal abnormalities
- 20 PFT Pulmonary Function Test
- 21 QOL Quality of life
- 22 VAS visual assessment score
- 23
- 24 Abstract
- 25 Background: High resolution computed tomography (HRCT) of the chest is
- 26 increasingly used in clinical practice for sarcoidosis. Visual assessment of chest HRCTs
- 27 in patients with sarcoidosis has high inter- and intra-rater variation. Radiomics offers a
- 28 reproducible quantitative assessment of HRCT lung parenchyma and could be useful as
- 29 an additional summary measure of disease. We develop radiomic profiles on HRCT and
- 30 map them to radiologic, clinical, and patient reported outcomes.

Research Question: Can radiomic analysis of chest HRCT cluster patients into groups
that are related to radiologic, clinical, and patient reported outcomes?

Study Design and Methods: Three-dimensional radiomic features were calculated on 33 chest HRCT for both lungs from sarcoidosis cases enrolled in the Genomic Research in 34 Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study (N=320). Robust and 35 36 sparse K-means was used to cluster sarcoidosis cases using their radiomic profiles. 37 Differences in patterns on visual assessment (VAS) by cluster were identified using chisquared tests. Linear regression investigated how pulmonary function tests and patient 38 39 reported outcomes differed between clusters with and without adjustment for other 40 radiologic quantification.

Results: Radiomic-based clustering identified four clusters associated with both 41 Scadding stage and Oberstein score (P<0.001). One of the clusters had markedly few 42 43 abnormalities. Another cluster had consistently more abnormalities along with more Scadding stage IV. Average pulmonary function testing (PFT) differed between clusters, 44 45 even after accounting for Scadding stage and Oberstein score (P < 0.001), with one 46 cluster having more obstructive disease. The most discriminative radiomic measures 47 explained 10-15% of the variation in PFT beyond demographic variables. Shortness of 48 breath, fatigue, and physical health differed by cluster (P < 0.014).

Interpretation: Radiomic quantification of sarcoidosis identifies new subtypes
representative of existing radiologic assessment and more predictive of pulmonary
function. These findings provide evidence that radiomics may be useful for identifying
new imaging-based disease phenotypes.

53

54 Abstract word count: 295

56	Sarcoidosis is a granulomatous interstitial lung disease which affects ~ 110 thousand
57	individuals in the United States ¹ . Typical diagnosis is between 30-50 years of life,
58	resulting in decreases in quality of life (QOL) and productivity ² . Pulmonary disease
59	occurs in over 90% of those with sarcoidosis ³ with significant morbidity and mortality.
60	Currently, visual assessment of chest radiography (CXR) is used to quantify lung
61	abnormalities standardized via the Scadding staging ⁴ . Substantial variation exists in CT-
62	based radiographic patterns within each Scadding stage limiting its utility in predicting
63	prognosis even in the extreme stages ⁵ .

64

Chest high resolution computed tomography (HRCT) is increasingly used in clinical 65 66 practice to monitor disease as it offers more detailed visualization of parenchymal abnormalities (PA) compared to CXR^{4,6–8}. As with CXR, visual assessment of chest 67 HRCT is used to evaluate abnormalities although there are limited standardized scoring 68 69 metrics^{4,9,10}. This is due in part to the diverse and heterogeneous patterns present on chest HRCT in sarcoidosis, often with multiple patterns noted. These complexities result 70 71 in high inter- and intra-rater variation¹¹. Recently, a Delphi study was undertaken to 72 define phenotypes based on visual assessment, yet without assessment of clinical 73 utility¹². As not all patients have access to expert visual interpretation, more automated 74 systems that quantify sarcoidosis chest HRCT could decrease variation and make 75 HRCT more usable in routine clinical care.

76

Radiomics is when large numbers of quantitative features are extracted from medical
 images¹³. A radiomics panel computes summary measures of the distribution of the

Hounsfield units (HU) along with summary measures of the spatial relationships of
neighboring voxels¹⁴. The result is a characterization of image texture.

81

82	Radiomics have proved useful for quantifying HRCT in emphysema ⁷ , idiopathic
83	pulmonary fibrosis ^{15,16} , interstitial lung disease ^{17,18} , diffuse lung disease ¹⁹ and cancer ²⁰ .
84	Ryan et al. ²¹ showed the potential utility of radiomics in sarcoidosis, comparing radiomic
85	measures between sarcoidosis patients and controls. It remains unclear whether
86	radiomics also has the potential to differentiate varied phenotypes within sarcoidosis
87	patients and how radiomics relates to visual assessment (VAS). Radiomic profiles within
88	patients with sarcoidosis that correlate with VAS, pulmonary function testing (PFT), and
89	patient reported outcomes (PRO) would indicate that radiomics may serve as a useful
90	refined measure to track change in the lung parenchyma over time than is possible with
91	visual assessment.
92	
93	The goal of this study was to develop a radiomic profile of chest HRCT in sarcoidosis
94	using a phenotypically-diverse population of sarcoidosis participants from the Genomic
95	Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study ²² . We
96	employ statistical clustering techniques and investigate the clinical utility of the clusters
97	by quantifying their association with VAS, PFT and PRO ^{23,24} .
98	

99 Study Design and Methods

100

101 Study design and participants

102

103	The sarcoidosis population was recruited in the multicenter NHLBI-funded GRADS
104	study ²² as cross-sectional observational cohort (N=368). This ancillary study has
105	GRADS approval and all participants provided informed consent (IRB approval HS-2779
106	and HS-2780). More details of this cohort can be found in e-Appendix 1.
107	
108	To comply with image biomarker standardization initiative (IBSI) recommendations ²⁵
109	details of the HRCT acquisition, processing and segmentation can be found in e-
110	Appendix 1 and e-Tables 1 and 2. GRADS' visual assessment score (VAS; Table 3, e-
111	Appendix 1, e-Tables 3 and 4) was used to quantify overall Oberstein score ^{5,22} along
112	with additional information regarding presence of lymphadenopathy (LN), airway and
113	vasculature distortion (AD), and PA (Table 3). Scadding stage was evaluated at the site
114	using CXR (e-Appendix1).
115	
116	PFT included pre-bronchodilator (pre-BD) forced expiratory volume at one second
117	(FEV1), forced vital capacity (FVC), the ratio of FEV1 to FVC, and post-BD diffusing
118	capacity of the lungs for carbon monoxide (DLCO). The PROs included the
119	gastroesophageal reflux disease questionnaire (GERDQ) ²⁶ , the University of California
120	San Diego Shortness of Breath Questionnaire (SOBQ) ²⁷ , two measures of fatigue (the
121	Fatigue Assessment Scale [FAS] ²⁸ and Patient-Reported Outcomes Measurement
122	Information System fatigue profile [PROMIS] ²⁹), the Cognitive Failure Questionnaire
123	(CFQ) ³⁰ , and the SF-12 ^{31,32} physical and mental subscales. The final analysis dataset

included N=320 patients who had an analyzable HRCT and clinical data (e-Figure 1).

125

126 Radiomic Analysis

We computed 44 first-order and 239 gray-level co-occurrence matrix (GLCM) radiomic
features on each lung (566 features) using the lungct and RIA packages in R^{33–36}.
These are open-source packages with published documentation and permit perfect
reproducibility with transparent implementation, aligning with IBSI goals. Furthermore,
this allowed a fully R based analysis pipeline and provided a more comprehensive

132 radiomic panel. Radiomic features beyond those typically used in neuroscience and

133 cancer and previously standardized by IBSI may be important in diffuse pulmonary

disease. For consistency with package documentation, we use the nomenclature of the

135 RIA package.

136

To calculate the gray level co-occurrence matrix (GLCM) features, the Hounsfield units
from each HRCT were discretized into 16 bins with equal relative frequencies; then, the
features were calculated in 13 directions, assuming a voxel distance of one; these
features were summarized using the mean statistic ^{34,35}.

141

The R ez.combat function harmonized radiomic measures across scanners^{37–39}, while
preserving the biological variability in age, height, BMI, sex, race-ethnicity and GRADS
phenotype (e-Table 2).

145

146 Radiomic features were high-dimensional and repetitive (Figure 1). We used a

147 decorrelation filter⁴⁰ (e-Appendix 1) that prioritized first-order over second-order features

148	to identify a representative feature subset for analysis. This reduced the features to 99.
149	We used robust and sparse k-means ⁴¹ to cluster participants (R package, RSKC). For
150	outlier robustness, trimming was set at 0.1. The optimal bound on feature weights (9.5)
151	and number of clusters (4) were simultaneously selected using a permutation approach
152	and BCS-based Gap statistic ⁴¹ after standardization ⁴² . Standardization was performed
153	with respect to the permutation reference to permit comparability across bounds and
154	cluster numbers. The top five discriminative features were selected for further
155	investigation.
156	Statistical Analysis and Validation
157	Descriptive statistics on VAS were computed by cluster and simulated Fisher's exact
158	tests used to assess cluster differences. Linear regression quantified associations
159	between cluster, Scadding stage, and Oberstein Score, and each of the outcomes. We
160	fitted univariable models with cluster, Scadding stage, or Oberstein score and then
161	modeled them together to determine if cluster association remained significant
162	accounting for other radiologic findings. Each outcome was modelled separately using a
163	complete case analysis. Linear regression quantified associations between
164	discriminative features and outcomes. All models were adjusted for age, sex,
165	race/ethnicity (e-Appendix 1), height, and BMI. Analyses were conducted in R ³⁶ .
166	
167	This work was an unsupervised problem, which made traditional training and test

validation approaches difficult given unknown true groupings. Instead, we conducted

- 169 internal validation by applying our analysis pipeline under various conditions and with
- 170 bootstrapped samples (e-Appendix 1).

171

172 Results

- 173 Tables 1-2 shows the characteristics of the study population (N=320), 146 (46%) self-
- identified as male, 220 (68.8%) self-identified as non-Hispanic white, 76 (24%) as black,
- 175 15 (4.7%) as Hispanic, and 9 (2.8%) as one of Asian, American Indian, Alaska Native,
- not identifying a single primary race or missing (N=2). The average age was 53 (SD=10)
- 177 years, average height 67.0 in (SD=4.0) and average BMI 30.6 kg/m² (SD=6.5). By
- design participants spread across Scadding stages, with 43 (14%) stage 0, 63 (20%)
- 179 stage 1, 92 (29%) stage 2, 44 (14%) stage 3 and 75 (24%) stage 4. The average FEV1
- 180 was 2.62 L (SD=0.89), FVC 3.57 L (SD=1.07), and DLCO 80.31 (SD=23.97). The
- 181 population predominantly demonstrated non-obstructive FEV1/FVC ratio (N=235; 73%).
- 182

183 Radiomic Based Clustering

184 We identified four clusters (Table 1). Ordered from highest FVC to lowest, 56 (17.5%)

185 patients were cluster 1, 110 (34.3%) cluster 2, 54 (16.9%) cluster 3, and 100 (31.3%)

186 cluster 4. Cluster was associated with Scadding stage (*P*<0.001), but not a direct

- reflection of Scadding stage (Table 1). Descriptively, cluster 3 had the highest
- percentage of Scadding stage IV (48%). Clusters 1 and 2 each had approximately 60%
- of the patients with a Scadding stage of I or II, a higher proportion of stage 0, and
- 190 limited Scadding stage IV present. Cluster 3 had the second highest observed Scadding
- 191 stage IV (40%) with a similar percentage of Scadding stage II compared to clusters 1

192 and 2 (~30%).

193

194 Radiomic clustering and VAS

195	When descriptively investigating VAS patterns, the clusters reflected increased
196	presence of VAS abnormalities with cluster 1 having low presence of nearly all airway
197	and vascular distortions (AD) and PA and much lower average Oberstein scores than
198	clusters 2-4 (Table 3; P <0.001). Cluster 2 reflected some increase in AD and PA with
199	clusters 3 and 4 having a higher presence of AD and PA. For example, cluster 4 had at
200	least double the presence of AD and PA compared to cluster 2. After adjustment for
201	demographics, average Oberstein score for cluster 3 was 1.98 (SE=0.48) units and
202	cluster 4 was 3.15 (SE=0.39) units higher than cluster 2 (p<0.001).
203	
204	Associations with PFT and PRO
205	After adjustment for demographics, average PFT differed between clusters (Figure 2;
206	P<0.001). Clusters 2 and 3 had ~0.3 L lower average FVC compared to clusters 1 and 4
207	had ~0.9 L lower average FVC compared to cluster 1. Cluster 2 had ~0.2 L lower
208	average FVC compared to cluster 1 and cluster 3 had a larger decline with an average
209	FEV1 ~0.5 L lower than cluster 1. Cluster 4 had the lowest average FEV1 and ~0.8 L $$
210	lower than cluster 1. DLCO had a similar pattern to FVC. Cluster 3 had the most
211	FEV1/FVC based obstruction (54%) with clusters 1 and 2 having the same amount of
212	obstruction (16%) and cluster 4 falling in the middle (32%).
213	
214	After adjustment for demographics, PROs also differed between clusters but not
215	consistently (Figure 3). Fatigue and Average shortness of breath (SOBQ) differed

between clusters (P<0.014). Clusters 2 and 4 had a fatigue score that was more than 3

units lower on average compared to cluster 1 (p<0.016). Cluster 4 also had an average
SOBQ ~12 units higher than cluster 1 (p=0.003).

219

220	The clusters remained significantly associated with PFT after adjusting for Scadding
221	stage (Figure 2; P<0.001) or Oberstein score (Figure 2; P<0.001) and after adjusting for
222	both simultaneously (Figure 2; <i>P</i> <0.001). Oberstein score was not significantly
223	associated with FVC after adjustment for cluster (P =0.59) and became even less
224	significant after further adjustment for Scadding stage (P=0.88). However, Scadding
225	stage was significantly associated with FVC after adjustment for cluster and Oberstein
226	score (<i>P</i> =0.019). The findings for Oberstein score with DLCO were like those of FVC.
227	For FEV1, Oberstein score was still significantly associated after adjustment for cluster
228	(P=0.011) but became insignificant after additional adjustment for Scadding stage
229	(P=0.21). Scadding stage remained significant in all models (P<0.001). For FEV1/FVC,
230	all three assessments (radiomics, Scadding, and Oberstein score) were significant
231	(<i>P</i> <0.016).

232

Cluster also remained associated with fatigue and SOBQ score after adjustment for
Scadding and Oberstein (*P*<0.038; Figure 3).

235

The five most discriminatory radiomic features included kurtosis, which is a measure of shape of the distribution of the HU from an image, as well as four summary measures from the gray level co-occurrence matrix (GLCM). The GLCM measure spatial correlation and similarity of the HU in image voxels near each other. Image visualization

240	of cases with different values of kurtosis and two GLCM measures are shown in Figure
241	4 with distribution of HU in e-Figure 2 for maximum, median and minimum kurtosis
242	levels in our population. The images visibly show the increase in observable PA (Figure
243	4) with lower kurtosis. In addition, Figure 5 shows how Oberstein Score separates
244	based on kurtosis and GLCM Min. GLCM Min appears to be most related to severity
245	with higher Oberstein score mapping with higher GLCM Min and Scadding stage is, in
246	general, not associated with either measure.
247	
248	The discriminatory radiomic measures were jointly associated with FVC, FEV1,
249	FEV1/FVC and DLCO (P<0.001; Table 4 and e-Table 5 for PRO). The radiomic
250	measures explained between 10 to 15% more variation in PFT than adjustment for
251	demographics (age, race, sex, height and BMI) only. For comparison, Scadding stage
252	explained between 4% and 12% more variation in PFT and Oberstein score explained
253	between 2% and 8% more variation in PFT.
254	
255	Validation of Clustering
256	Detailed results can be found in e-Appendix 2, e-Figure 3. The validation analysis
257	suggested only mild sensitivity of clustering to the analysis pipeline. There is more
258	sensitivity to bootstrapped samples in how the sample is divided into clusters; however,
259	cluster consistently remained a significant predictor of FVC across all sources of
260	random perturbations in the pipeline. In all validation cases the proportions of P-values
261	less than 0.01 were 100%.

262

.

263 Discussion

Radiographic manifestations in sarcoidosis are protean. As a result, traditionally VAS is 264 265 used for image characterization and not standardized. The utility of VAS in sarcoidosis 266 is limited by the intra-observer and inter-observer variability. Radiomics is a more 267 reproducible and computationally efficient approach to characterize HRCT. We used 268 radiomics to characterize images from a large, phenotypically diverse cohort of 269 sarcoidosis subjects and demonstrated that radiomics are associated with VAS, clinical 270 and patient reported outcomes of disease. Using a common unsupervised learning approach⁴¹, we identified four radiomic based clusters. These clusters differed 271 272 significantly by PFT, fatigue, and shortness of breath, two PROs. Notably, each cluster 273 included a range of Scadding stages and cluster remained significantly associated with 274 PFT after accounting for Scadding stage and Oberstein score. These data suggest that radiomics represents radiographic abnormalities that differ from Scadding stage and 275 276 may be a better representation of image characterization to explain PFT and PRO.

277

278 A holistic assessment of the clusters showed two lower severity and two higher severity 279 clusters (Table 5). One high severity cluster (4) had significant fibrosis, substantial presence of AD and PA on VAS, and decreased PFT, which resulted in more shortness 280 of breath and fatigue. Cluster 3 represented those with obstructive spirometry and more 281 282 presence of AD and PA than clusters 1 and 2, moderate fibrosis, and the lowest 283 FEV1/FVC ratio. These interpretations have similarities to another recent attempt to subtype using clinical characteristics⁴³. Unlike our work, that work had no radiomics or 284 285 VAS. We both several low severity clusters with minimal PA. We both found an

286	obstructive cluster and a severe fibrotic cluster. More recently, HRCT VAS phenotypes
287	were proposed via a Delphi consensus study ¹² . That work defined two major groups,
288	those with fibrotic versus non-fibrotic findings, similar to our clusters with fibrotic (3 and
289	4) versus more non-fibrotic (1 and 2) findings. However, the VAS of their various
290	subtypes of non-fibrotic and fibrotic CT findings were included in a number of our
291	clusters. This may reflect the power in our sample size to define subtypes or possibly
292	that these phenotypes or VAS overlap as noted in our study.
293	
294	Demographic characteristics of the individual explained a sizable amount of the
295	variation observed in PFT (R ² =50-60%). Radiomics also explained a significant amount
296	of additional variation in PFT (10-50%). This additional amount of variation explained is
297	consistent with other quantitative imaging approaches such as CALIPER ¹⁷ and those
298	used for investigations of other lung conditions such as systemic sclerosis ⁴⁴ and diffuse
299	interstitial lung diseases ⁴⁵ .
300	
301	Except in lung cancer research, much of the quantitative CT image analysis has
302	focused on HU density ^{18,44} . We included summarization of both density and spatial
303	characterization. More measures of GLCM appeared discriminative in the cluster
304	analysis than densitometry measures. This implies that texture is perhaps more useful
305	for differentiating PA in sarcoidosis.
306	

decreased FVC and DLCO, it is plausible that as kurtosis decreases, more severe PA

Although it remains speculative as to why decreased kurtosis is associated with

307

are present that impact lung function. As kurtosis decreases, more severe PA are visual
present that may impact the function of the lung (Figure 4). Severe PA in sarcoidosis
are observed as higher HU values. In e-Figure we observed the presence of a higher
frequency of higher HU values dampening the peak in the HU distribution and leading to
a lower kurtosis. In addition, GLCM Min appears likely to measure disease severity
based on the visual patterns with Oberstein in Figure 5.

315

316 The associations with cluster and PROs were less consistent, although important 317 patterns emerged. Cluster 4 demonstrated decreased QOL (SF-12 physical) and worse 318 shortness of breath (SOBQ), findings that are consistent with worse lung function and 319 VAS scores in this cluster. Cluster explained substantially less variation in PROs (0 to 320 8%) compared to PFTs. While the tools we used to measure PROs are validated and used widely in sarcoidosis, they are not generally correlated with objective measures of 321 lung function⁴⁶. As an example, fatigue is a known multi-factorial PRO in sarcoidosis 322 323 and may impact a number of other PRO^{46,47}. Our finding that cluster is associated with 324 decreased physical function and increased shortness of breath provides 325 encouragement that more detailed characterization of lung abnormalities, like we 326 developed here, could contribute to a better understanding of the current disconnect 327 between measures of lung function and patient experiences.

328

This study had several strengths. To our knowledge, this was the largest cluster of sarcoidosis patients with research grade HRCT available allowing for a full 3-D based quantitative analysis. Radiomic and other quantitative imaging approaches have a major

332 strength in that they can be computed in a time efficient and reliable, reproducible automated procedure. The radiomics package in R took only 3 minutes to compute all 333 334 the 3-D radiomics measures. This means large quantities of scans can have radiomic 335 profiles computed for aiding in decisions on what scans the radiologist might prioritize for further consideration for visual or clinician evaluation. 336 337 338 In addition to the high-quality and robust clinical data, the GRADS study also provides a 339 comprehensive and consistently collected set of patient reported outcomes, which reflect important aspects of treatment decision-making processes⁴⁸. The results 340 341 internally validated suggest our approach is not over fitting these data. 342 343 This study is not without limitations. The GRADS study relied on enrollment from 344 academic centers and could be skewed to a population that was referred for worse 345 disease or was near one of the centers, which were primarily localized to the Eastern 346 US. The demographic is predominantly white and of higher SES as a result and thus 347 may not provide full representation of the spectrum of disease. In addition, many 348 subjects had disease for a decade or longer and were treated. While the same protocol 349 was used across study sites for obtaining the CT images we studied, the scanners 350 themselves differed. Harmonization was performed to mitigate systematic differences 351 due to scanner type. In addition, the distribution of PFT measures is not dependent on 352 scanner type. As such, we expect any differences in the radiomic measures due to 353 scanner type to be non-differential as they relate to PFTs. Finally, the number of 354 clusters we identified may not directly translate to other populations of sarcoidosis or be

355	the unique optimal solution. There are multiple ways to choose the optimal number of
356	clusters. We used an alternative radiomics package with a broader set of measures.
357	However, not all these measures were part of IBSI work. We used open-source
358	software accessible to any reader for verification of our findings and to conduct
359	comparisons with other software.
360	
361	Interpretation
362	In summary, this work provides evidence that in sarcoidosis radiomic quantification is
363	useful for classifying abnormality of the lung along with pulmonary function and to a
364	lesser degree patient reported outcomes. Future work should evaluate the potential of
365	radiomics to capture small changes over time not easily detected by other assessment
366	to further evaluate the potential of radiomics serving as a clinically useful quantitative
367	measure of sarcoidosis presentation and progression.

369 **References**

- Erdal BS, Clymer BD, Yildiz VO, Julian MW, Crouser ED. Unexpectedly high
 prevalence of sarcoidosis in a representative U.S. Metropolitan population. *Respir Med* 2012;106(6):893–899.
- Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health
 Questionnaire: a new measure of health-related quality of life. *Am J Respir Crit Care Med* 2003;168(3):323–329.
- Wasfi YS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity.
 Chest 2006;129(5):1234–1245.
- Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136
 cases after five years' observation. *Br Med J* 1961;2(5261):1165–1172.
- Oberstein A, Zitzewitz H von, Schweden F, Müller-Quernheim J. Non invasive
 evaluation of the inflammatory activity in sarcoidosis with high-resolution computed
 tomography. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG 1997;14(1):65–72.
- Brent M, De Vries J, Lenters M, et al. Sarcoidosis: assessment of disease severity
 using HRCT. *Eur Radiol* 2003;13(11):2462–2471.
- 385 7. Sluimer I, Schilham A, Prokop M, Ginneken B van. Computer analysis of computed
 386 tomography scans of the lung: a survey. *IEEE Trans Med Imaging* 2006;25(4):385–
 387 405.
- Keijsers RGM, Heuvel DAF van den, Grutters JC. Imaging the inflammatory activity
 of sarcoidosis. *Eur Respir J* 2013;41(3):743–751.
- Moller DR. Negative clinical trials in sarcoidosis: failed therapies or flawed study
 design? *Eur Respir J* 2014;44(5):1123–1126.
- Nunes H, Uzunhan Y, Gille T, Lamberto C, Valeyre D, Brillet P-Y. Imaging of
 sarcoidosis of the airways and lung parenchyma and correlation with lung function.
 Eur Respir J 2012;40(3):750–765.
- 11. Van den Heuvel DA, Jong PA de, Zanen P, et al. Chest Computed Tomography Based Scoring of Thoracic Sarcoidosis: Inter-rater Reliability of CT Abnormalities.
 Eur Radiol 2015;25(9):2558–2566.
- Besai SR, Sivarasan N, Johannson KA, et al. High-resolution CT phenotypes in
 pulmonary sarcoidosis: a multinational Delphi consensus study. *Lancet Respir Med* [Internet] 2023 [cited 2024 Jan 9];0(0). Available from:
- 401 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00267-402 9/fulltext

- 403 13. Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. *Magn* 404 *Reson Imaging* 2012;30(9):1234–1248.
- 405 14. Haralick RM. Statistical and structural approaches to texture. *Proc IEEE* 406 1979;67(5):786–804.
- Park YS, Seo JB, Kim N, et al. Texture-based quantification of pulmonary
 emphysema on high-resolution computed tomography: comparison with densitybased quantification and correlation with pulmonary function test. *Invest Radiol*2008;43(6):395–402.
- Humphries SM, Yagihashi K, Huckleberry J, et al. Idiopathic Pulmonary Fibrosis:
 Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month
 Follow-up. *Radiology* 2017;285(1):270–278.
- 414 17. Ungprasert P, Wilton KM, Ernste FC, et al. Novel Assessment of Interstitial Lung
 415 Disease Using the "Computer-Aided Lung Informatics for Pathology Evaluation and
 416 Rating" (CALIPER) Software System in Idiopathic Inflammatory Myopathies. *Lung*417 2017;195(5):545–552.
- 418 18. Ash SY, Harmouche R, Vallejo DLL, et al. Densitometric and local histogram based
 419 analysis of computed tomography images in patients with idiopathic pulmonary
 420 fibrosis. *Respir Res* [Internet] 2017 [cited 2018 Jan 8];18. Available from:
 421 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340000/
- 422 19. Wang J, Li F, Doi K, Li Q. Computerized detection of diffuse lung disease in MDCT:
 423 the usefulness of statistical texture features. *Phys Med Biol* 2009;54(22):6881–
 424 6899.
- Lee G, Lee HY, Park H, et al. Radiomics and its emerging role in lung cancer
 research, imaging biomarkers and clinical management: State of the art. *Eur J Radiol* 2017;86:297–307.
- 428 21. Ryan SM, Fingerlin TE, Mroz M, et al. Radiomic measures from chest high429 resolution computed tomography associated with lung function in sarcoidosis. *Eur*430 *Respir J* 2019;54(2).
- 431 22. Moller DR, Koth LL, Maier LA, et al. Rationale and Design of the Genomic
 432 Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study.
 433 Sarcoidosis Protocol. *Ann Am Thorac Soc* 2015;12(10):1561–1571.
- 434 23. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K.
 435 Examination of the Dimensionality of Fatigue: The Construction of the Fatigue
 436 Assessment Scale (FAS). *Eur J Psychol Assess* 2004;20(1):39–48.
- 437 24. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement
 438 Information System (PROMIS) developed and tested its first wave of adult self-

- reported health outcome item banks: 2005-2008. *J Clin Epidemiol*2010;63(11):1179–1194.
- Zwanenburg A, Vallières M, Abdalah MA, et al. The Image Biomarker
 Standardization Initiative: Standardized Quantitative Radiomics for HighThroughput Image-based Phenotyping. *Radiology* 2020;295(2):328–338.
- 444 26. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the
 445 diagnosis and management of gastro-oesophageal reflux disease in primary care.
 446 *Aliment Pharmacol Ther* 2009;30(10):1030–1038.
- Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a New
 Dyspnea Measure: The UCSD Shortness of Breath Questionnaire. *Chest*1998;113(3):619–624.
- 450 28. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K.
 451 Examination of the Dimensionality of Fatigue: The Construction of the Fatigue
 452 Assessment Scale (FAS). *Eur J Psychol Assess* 2004;20(1):39–48.
- 29. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement
 Information System (PROMIS) developed and tested its first wave of adult selfreported health outcome item banks: 2005-2008. *J Clin Epidemiol*2010;63(11):1179–1194.
- 30. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures
 Questionnaire (CFQ) and its correlates. *Br J Clin Psychol* 1982;21(1):1–16.

459 31. Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey:
460 Construction of Scales and Preliminary Tests of Reliability and Validity. *Med Care*461 1996;34(3):220–233.

- 462 32. Ware J, Kosinski M, Turner-Bowker D, Gandek B. How to score SF-12 items. SF463 12 V2 Score Version 2 SF-12 Health Surv 2002;29–38.
- 33. Ryan SM, Vestal B, Maier LA, Carlson NE, Muschelli J. Template Creation for
 High-Resolution Computed Tomography Scans of the Lung in R Software. *Acad Radiol* 2020;27(8):e204–e215.
- 467 34. Kolossváry M, Kellermayer M, Merkely B, Maurovich-Horvat P. Cardiac Computed
 468 Tomography Radiomics: A Comprehensive Review on Radiomic Techniques. J
 469 Thorac Imaging 2018;33(1):26–34.
- 470 35. Kolossváry M, Karády J, Szilveszter B, et al. Radiomic Features Are Superior to
 471 Conventional Quantitative Computed Tomographic Metrics to Identify Coronary
 472 Plaques With Napkin-Ring Sign. *Circ Cardiovasc Imaging* 2017;10(12):e006843.

36. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
Vienna, Austria: R Foundation for Statistical Computing; 2018. Available from:
https://www.R-project.org/

- 476 37. Fortin J-P, Parker D, Tunç B, et al. Harmonization of multi-site diffusion tensor
 477 imaging data. *NeuroImage* 2017;161:149–170.
- 478 38. Fortin J-P, Cullen N, Sheline YI, et al. Harmonization of cortical thickness
 479 measurements across scanners and sites. *NeuroImage* 2018;167:104–120.
- 39. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression
 data using empirical Bayes methods. *Biostat Oxf Engl* 2007;8(1):118–127.
- 482 40. Lippit WL. Clustering with Highly Correlated Features. *MS Thesis Univ Colo* 2022;
- 483 41. Kondo Y, Salibian-Barrera M, Zamar R. RSKC : An R Package for a Robust and
 484 Sparse K-Means Clustering Algorithm. *J Stat Softw* [Internet] 2016 [cited 2020 May
 485 27];72(5). Available from: http://www.jstatsoft.org/v72/i05/
- 486
 42. Witten DM, Tibshirani R. A framework for feature selection in clustering. *J Am Stat* 487 *Assoc* 2010;105(490):713–726.
- 43. Lin NW, Arbet J, Mroz MM, et al. Clinical phenotyping in sarcoidosis using cluster
 analysis. *Respir Res* 2022;23(1):88.
- 490 44. Camiciottoli G, Orlandi I, Bartolucci M, et al. Lung CT Densitometry in Systemic
 491 Sclerosis: Correlation With Lung Function, Exercise Testing, and Quality of Life.
 492 Chest 2007;131(3):672–681.
- 45. Shin KE, Chung MJ, Jung MP, Choe BK, Lee KS. Quantitative Computed
 Tomographic Indexes in Diffuse Interstitial Lung Disease: Correlation With
 Physiologic Tests and Computed Tomography Visual Scores. *J Comput Assist Tomogr* 2011;35(2):266–271.
- 497 46. Thunold RF, Løkke A, Cohen AL, Hilberg O, Bendstrup E. Patient Reported
 498 Outcome Measures (PROMs) in Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis
 499 2017;34(1):2–17.
- Kampstra NA, Grutters JC, Beek FT van, et al. First patient-centred set of
 outcomes for pulmonary sarcoidosis: a multicentre initiative. *BMJ Open Respir Res*2019;6(1):e000394.
- 48. Wijsenbeek MS, Culver DA. Treatment of Sarcoidosis. *Clin Chest Med*2015;36(4):751–767.

506 Take-Home Points

- 507 Study Question: Is radiomics a useful quantitative approach for defining radiographic
- 508 subtypes in sarcoidosis?
- 509 Results: Radiomics find four radiographic subtypes in sarcoidosis that are related to
- 510 visual assessment and more predictive of clinical measures such as pulmonary function
- 511 that visual assessment.
- 512 Interpretation: Radiomics analysis suggests four subtypes of sarcoidosis ranging from
- 513 low severity with limited radiographic abnormality and normal pulmonary function to
- severe with significant abnormality on chest CT and either obstruction based on
- 515 pulmonary function or reduced pulmonary function with fibrotic presentation on image.

517

518 **Table 1:** Patient demographics by radiomic cluster, ordered from least severe (1) to

519 most severe (4) based on average FVC. Unless otherwise noted values are mean (SD).

Characteristic	Ν	Overall	1	2	3	4	P-
	miss						value
Sample Size		320	56	110	54	100	
FVC (L)	6	3.57 (1.14)	3.91 (1.16)	3.88 (1.08)	3.61 (1.27)	3.02 (0.92)	<0.001
Age (yr)	0	52.9 (9.9)	49.8 (10.6)	53.1 (9.9)	52.5 (9.8)	54.8 (9.3)	0.026
Female; N (%)		174 (54%)	37 (66%)	52 (47%)	36 (67%)	49 (49%)	0.021
Race/Ethnicity;	0						0.033
N (%)							
Asian, American		9 (2.8%)	0 (0%)	4 (3.6%)	1 (1.9%)	4 (4.0%)	
Indian, Alaska Native,							
or not identifying a							
single primary race							
Black		76 (24%)	12 (21%)	16 (15%)	13 (24%)	35 (35%)	
Hispanic		15 (4.7%)	2 (3.6%)	6 (5.5%)	1 (1.9%)	6 (6.0%)	
White	0	220 (69%)	42 (75%)	84 (76%)	39 (72%)	55 (55%)	
Height (in)	0	67.0 (4.0)	66.3 (4.2)	67.7 (4.2)	66.5 (3.7)	66.9 (3.7)	0.13
BMI (kg/m^2)	0	30.6 (6.5)	30.2 (7.4)	32.6 (5.7)	27.0 (5.8)	30.7 (6.4)	<0.001
Scadding; N (%)	3						<0.001
0		43 (14%)	9 (16%)	25 (23%)	4 (7.5%)	5 (5.0%)	
I		63 (20%)	16 (29%)	31 (29%)	7 (13%)	9 (9.0%)	
II		92 (29%)	17 (30%)	32 (30%)	15 (28%)	28 (28%)	
Ш		44 (14%)	12 (21%)	16 (15%)	6 (11%)	10 (10%)	
IV		75 (24%)	2 (3.6%)	4 (3.7%)	21 (40%)	48 (48%)	

521 **Table 2:** Summary measures of pulmonary function testing and self-reported outcomes

- 522 by radiomic cluster ordered from least severe (1) to most severe (4) based on average
- 523 FVC. Unless otherwise noted values are mean (SD).
- 524

	N Miss	Overall	1	2	3	4	<i>P</i> - value
Sample Size		320	56	110	54	100	
FEV1 (L)	6	2.62 (0.05)	2.98 (0.13)	2.96 (0.08)	2.44 (0.15)	2.14 (0.07)	<0.001
FVC (L)	6	3.57 (0.06)	3.91 (0.16)	3.88 (0.10)	3.61 (0.18)	3.02 (0.09)	<0.001
FEV1/FVC (%)	6	0.73 (0.01)	0.76 (0.01)	0.77 (0.01)	0.67 (0.02)	0.71 (0.01)	<0.001
Obstructive Type ^a ; N (%)	6	85 (27%)	9 (16%)	17 (16%)	27 (54%)	32 (32%)	<0.001
DLCO (mL/min/mmHg)	18	22.07 (0.45)	24.13 (1.03)	25.33 (0.66)	21.30 (1.01)	17.56 (0.76)	<0.001
FAS ^a	140	29.77 (0.41)	32.46 (1.29)	28.95 (0.66)	30.06 (0.91)	29.24 (0.65)	0.038
GERDQ⁵	1	7.07 (0.12)	7.04 (0.30)	7.09 (0.17)	6.72 (0.27)	7.25 (0.23)	0.5
CFQ°	3	32.79 (0.95)	34.57 (1.87)	34.14 (1.58)	32.50 (2.22)	30.44 (1.93)	0.4
SOBQ ^d	17	26.28 (1.31)	22.08 (3.13)	19.94 (1.80)	26.98 (3.12)	35.04 (2.56)	<0.001
PROMIS Fatigue [®]	38	25.51 (0.52)	25.82 (1.28)	23.96 (0.82)	26.80 (1.35)	26.18 (0.93)	0.2
SF12-Physical ^f	6	41.70 (0.63)	44.78 (1.55)	42.23 (1.10)	42.80 (1.49)	38.77 (1.07)	0.009
SF12-Mental ^h	6	48.12 (0.56)	47.13 (1.21)	48.60 (0.90)	47.33 (1.49)	48.56 (1.09)	0.7

525

^aFAS range 5 – 50, higher values indicate more fatigue; ^bGERDQ range 0 – 18, higher values

- 527 indicate a higher likelihood of GERD; °CFQ range 0 -100, higher indicates more cognitive
- 528 failure; ^d SOBQ range 0 120, higher values indicate more shortness of breath; ^e PROMIS
- 529 Fatigue range 10-50, higher values indicate more fatigue; ^fSF12-Physical-For general U.S.

- 530 population, mean = 50, SD = 10 and higher values indicate better physical QOL; ⁹SF12-Mental-
- 531 For general U.S. population, mean = 50, SD = 10 and higher values indicate better mental
- 532 QOL.
- 533

- 534 **Table 3:** Distribution of VAS measures by radiomic cluster. Three participants were missing
- 535 VAS and Scadding stage. All measures represent the abnormality was present (vs. absent) and
- 536 are presented as N (%) unless otherwise noted. LN = lymphadenopathy; BVB =
- 537 Bronchovascular Bundle

538

Characteristic	Overall	1	2	3	4	<i>P</i> - value
Sample Size	317	56	108	53	100	
Mediastinal LN	172 (54%)	19 (34%)	60 (56%)	29 (55%)	64 (64%)	0.003
Hilar LN	135 (43%)	14 (25%)	46 (43%)	26 (49%)	49 (49%)	0.017
Micronodule	147 (46%)	23 (41%)	46 (43%)	29 (55%)	49 (49%)	0.4
Airway and Vascular Distortion (AD)						
BVB Distortion	202 (64%)	19 (34%)	53 (49%)	43 (81%)	87 (87%)	<0.001
Traction Bronchiectasis	129 (41%)	6 (11%)	25 (23%)	32 (60%)	66 (66%)	<0.001
Parenchymal Opacity and Distortion (PD)						
Ground Glass	110 (35%)	5 (8.9%)	22 (20%)	21 (40%)	62 (62%)	<0.001
Honeycombing	25 (7.9%)	0 (0%)	2 (1.9%)	4 (7.5%)	19 (19%)	<0.001
Reticular Abnormality	88 (28%)	3 (5.4%)	17 (16%)	21 (40%)	47 (47%)	<0.001
Mosaic Attenuation	86 (27%)	10 (18%)	18 (17%)	14 (26%)	44 (44%)	<0.001
Interlobular Septal Thickening	54 (17%)	5 (8.9%)	14 (13%)	7 (13%)	28 (28%)	0.007
Oberstein Overall; Mean (SE)	4.23 (0.18)	2.11 (0.32)	2.95 (0.26)	5.32 (0.44)	6.23 (0.28)	<0.001

541 Table 4: Results of the multivariable regression analysis (coefficients and SE's) of

542 the five discriminatory radiomic measures for PFT.^d

	GLCM	GLCM Inv	Kurtosis	GLCM	GLCM Min	P-value	Rsq	Rsq -
	Gaussian	Gaussian-E		Sum				base
				Energy				
FVC	-0.02 (0.11)	-0.06 (0.08)	0.44 (0.08) ^a	0.04 (0.09)	-0.06 (0.08)	<0.0001	0.726	0.622
FEV1	-0.16 (0.10)	-0.17 (0.08) ^c	0.08 (0.07)	0.01 (0.08)	0.23 (0.08) ^a	<0.0001	0.619	0.514
FEV1/FVC	-0.04 (0.02) ^b	-0.03 (0.01) ^b	-0.07 (0.01) ^b	-0.02 (0.01)	0.09 (0.01) ^b	<0.0001	0.199	0.049
DLCO	-2.23 (0.85) ^a	-1.65 (0.65) ^b	1.40 (0.62) ^c	0.50 (0.70)	-0.04 (0.68)	< 0.0001	0.636	0.541

⁵⁴³ ^a *P*-value <0.001; ^b *P*-value<0.025; ^c *P*-value<0.035. ^dEach linear regression model

544 included all five radiomic features and was additionally adjusted for age, gender,

race/ethnicity, BMI and height. Bolded cells are statistically significant (p-values in the

footnote). GLCM Gaussian is the sum of the GLCM with a Gaussian weight applied.

547 GLCM-Inv Gaussian-E is the sum of the GLCM for the inverse Gaussian weighting

scheme. GLCM Sum Energy is the sum of the squared values in the GLCM and a

549 measure of uniformity. GLCM Min is the minimum of the GLCM. P-value is for the partial

550 F-test of significance of any of the five radiomic measures.

551

553 Table 5: Holistic interpretation of radiomic clusters in terms of VAS, PFT, and

554 **PRO measures.**

Cluster #	Cluster Description	Directional changes in characteristics	Severe Disease Features ^a
1	Low severity with less LN, less PA and AD and limited shortness of breath (PRO)	Oberstein Score $\downarrow \downarrow$ Scadding stage 1,2 FEV1, FVC, DLCO↑ LN \downarrow vs. Cluster 3,4 SOBQ \downarrow vs. Cluster 4 Age \downarrow & Female↑	SOBQ SOBQ SCad 1, 2 SCad 1, 2 SCad
2	Low severity with more LN, smaller increases in PA and AD and limited PFT and shortness of breath	Oberstein Score \downarrow Scadding stage 1,2 FEV1, FVC, DLCO \uparrow LN \uparrow vs. Cluster 1 SOBQ \downarrow vs. Cluster 4 Age \rightarrow , Balanced Sex	↑ PFT ↓ Scad 1, 2 ↑ VAS
3	Severe obstructive, fibrotic presentation with significant PA, AD, and decreased PFT	Oberstein Score $\uparrow vs. 1, 2 \downarrow 4$ Scadding stage 2,4 FEV1/FVC $\downarrow \downarrow$ (Obstruction \uparrow), PFT \downarrow LN \rightarrow vs. 2 & 4 Age \rightarrow , Female \uparrow	SOBQ VAS VAS
4	Severe PA and AD with significant fibrosis; low PFT and increased shortness of breath and fatigue.	Oberstein Score $\uparrow \uparrow$ Scadding stage 4 FEV1, FVC, DLCO $\downarrow \downarrow$ LN \rightarrow vs. 2 & 3 SOBQ, Fatigue \uparrow Age \rightarrow , Balanced Sex	↓↓ PFT ↓↓ SoBQ, Fatigue ↓↓VAS

^a No fill represents similar to least impairment observed. Lined shading represents moderate

impairment or ~25-50% prevalence for Scadding stage. Dark shading represents similar to

557 worst impairment observed or ~50% prevalence for Scadding stage.

Figure Legends

Figure 1: Heat map of the correlation between different radiomic measures for the entire population.

Figure 2: Radiomic cluster differences in average PFT values (columns) from regression models with adjustment for demographics (top row), then additionally adjusted for either Scadding stage or Oberstein score (middle two rows), then adjusted for both Scadding stage and Oberstein score (bottom row). The significance of the cluster differences from cluster 1 are in green (p>0.05) and blue (p<0.05). The bottom text in each panel is the overall p-value for the association between clustering and PFT outcome along with the R².

Figure 3: Radiomic cluster differences in average PRO values (columns) from regression models with adjustment for demographics (top row), then additionally adjusted for either Scadding stage of Oberstein score (middle two rows), then adjusted for both Scadding stage and Oberstein score (bottom row). The significance of the cluster differences from cluster 1 are in green (p>0.05) and blue (p<0.05). The bottom text in each panel is the overall p-value for the association between clustering and PFT outcome along with the R².

Figure 4: CT images in axial orientation for three patients with minimum, median, and maximum values for GLCM Gaussian (left column), the GLCM Inverse Gaussian, and the kurtosis.

Figure 5: Separation of Oberstein score and Scadding based kurtosis (y-axis) and GLCM-Min (x-axis) two of the five most important radiomic variables in defining clusters. Colors represent the Oberstein score and Scadding stage.





Significance 🔶 FALSE 🄶

TRUE





